Marker Therapeutics Files 8-K on Financials

TL;DR

Marker Therapeutics dropped an 8-K on May 15th detailing their financials. Check it out.

AI Summary

Marker Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 9350 Kirby Drive, Suite 300, Houston, Texas.

Why It Matters

This 8-K filing provides crucial updates on Marker Therapeutics' financial performance and condition, which is essential for investors to assess the company's stability and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial information and does not indicate any immediate or significant risks.

Key Players & Entities

• Marker Therapeutics, Inc. (company) — Registrant
• May 15, 2024 (date) — Date of Report
• 9350 Kirby Drive, Suite 300 Houston, Texas 77054 (address) — Principal executive offices
• Delaware (jurisdiction) — State of incorporation
• 001-37939 (company_id) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar

Filing Documents

• tm2414438d1_8k.htm (8-K) — 24KB
• tm2414438d1_ex99-1.htm (EX-99.1) — 85KB
• tm2414438d1_ex99-1img001.jpg (GRAPHIC) — 20KB
• tm2414438d1_ex99-1img002.jpg (GRAPHIC) — 6KB
• tm2414438d1_ex99-1img003.jpg (GRAPHIC) — 6KB
• tm2414438d1_ex99-1img004.jpg (GRAPHIC) — 6KB
• tm2414438d1_ex99-1img005.jpg (GRAPHIC) — 6KB
• tm2414438d1_ex99-1img006.jpg (GRAPHIC) — 6KB
• tm2414438d1_ex99-1img007.jpg (GRAPHIC) — 6KB
• 0001104659-24-062001.txt ( ) — 370KB
• mrkr-20240515.xsd (EX-101.SCH) — 3KB
• mrkr-20240515_lab.xml (EX-101.LAB) — 33KB
• mrkr-20240515_pre.xml (EX-101.PRE) — 22KB
• tm2414438d1_8k_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On May 15, 2024, Marker Therapeutics, Inc. (the " Company ") reported financial results for the quarter ended March 31, 2024 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference. The information in this Item 2.02 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated May 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: May 15, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR